NCT05409196 - Phase 1 Trial for Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Oral Shigella/ETEC Combination Vaccine to Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 16, 2020

Primary Completion Date

June 21, 2021

Study Completion Date

June 21, 2021

Conditions

Diarrheal Disease, InfectiousGastrointestinal DiseaseReactive Arthritis

Interventions

BIOLOGICAL

ShigETEC live, attenuated, oral vaccine

Vaccine or placebo will be delivered orally as a single dose in Stage 1 and between 2 and 4 doses at 3-day intervals in Stage 2 of the Study.

DRUG

Placebo

Vaccine or placebo will be delivered orally as a single dose in Stage 1 and between 2 and 4 doses at 3-day intervals in Stage 2 of the Study.

Trial Locations (1)

Debreceni Egyetem, Klinikai Központ, Belgyógyászati Klinika, Klinikai Farmakológiai Részleg, Debrecen